# Unresponsive Alopecia Areata Treated Successfully with Liquid Nitrogen Cryotherapy: A Study of Five Patients

#### Vijay Zawar<sup>1</sup>, Jaya Suresh Bharati<sup>2\*</sup>, Manoj Pawar<sup>3</sup>, Shrikant Kumavat<sup>4</sup> and Joy Das<sup>2</sup>

 <sup>1</sup>Professor and Head, Department of Dermatology, Venerology and Leprology, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Nashik - 422003, Maharashtra, India
<sup>2</sup>Former PG Resident, Dermatology, Venerology and Leprology, Dr. Vasantrao Pawar Medical College and Hospital and Research Centre, Adgaon, Nashik – 422003, Maharashtra, India; drjayabharati92@gmail.com
<sup>3</sup>Assistant Professor, Department of Dermatology, Venerology and Leprology, Dr. Vasantrao Pawar Medical College Hospital and Research Centre, Nashik – 422003, Maharashtra, India;
<sup>4</sup>Senior Resident, Department of Dermatology, Venerology and Leprology, Dr. Vasantrao Pawar Medical College Hospital and Research Centre, Nashik – 422003, Maharashtra, India

#### Abstract

**Introduction**: Alopecia Areata (AA) is one of the most common form of hair loss seen in dermatology. Treatment failures can occur with almost every conventional therapy, either singly or in combination. **Aims and Objectives:** To study the clinical profiles and management outcome of Liquid Nitrogen Cryotherapy (LNC) for the treatment of unresponsive cases of AA. **Materials and Methods:** A prospective study was conducted on five patients who showed no response to conventional topical treatment for six months. The subjects were enrolled in the study after written consent. Clinical photographs were recorded at each visit. Patients were given 3-5 sittings of LNC at 2 week intervals. Each session consisted of dual freeze thaw cycles of 15 seconds each, with a cryospray technique following application of topical anaesthetic cream. Suitable antibiotics and anti-inflammatory agents were prescribed post-operatively for five days. The clinical response was evaluated by using regrowth scale at 4<sup>th</sup> week and 8<sup>th</sup> week. Final end point evaluation of patient post 3 months after the last treatment session was done to observe sustained regrowth of hair. **Results**: Five patients were recruited, out of which three patients showed an excellent response, 1 each had a satisfactory response and a fair response respectively. Commonly seen adverse effects were slight pain, erythema, edema, erosion, crusting, dyspigmentation/hypopigmentation, which were transient and did not require withdrawal of treatment. **Conclusion**: Liquid Nitrogen Cryotherapy is a cheaper, easily available with transient adverse effects and can be worth trying in unresponsive Alopecia Areata.

Keywords: Alopecia Areata(AA), Liquid Nitrogen Cryotherapy (LNC), Unresponsive

## 1. Introduction

Alopecia Areata (AA) is one of the most common form of non-scarring hair loss accounting for 25% of all the alopecia cases<sup>1.2</sup>. Etiopathogenesis of AA consists of autoimmunity, genetic predisposition and environmental factors<sup>2</sup>. If AA is not treated, it can progress to Alopecia Totalis (AT) or Alopecia Universalis (AU) in 5–10% patients<sup>2</sup>. There are different treatment modalities like topical corticosteroids, intralesional steroids, minoxidil, tacrolimus, contact sensitizers, irritants, photochemotherapy, immunomodulators like methotrexate, alefacept, azathioprine, systemic Janus Kinases, Signal Transducer and Activator of

<sup>\*</sup>Author for correspondence

Transcription (JAK/STAT) pathway inhibitors and tumor necrosis factor-alpha inhibitors  $(TNF-\alpha)^3$ . Although AA is a commonly encountered disease, its course and prognosis is unpredictable and the available treatment is also not uniform. Cryotherapy has been used as a mechanical intervention in treatment of AA. It exerts cold inflammation over. It exerts cold inflammation over the lesional skin and helps in vasodilatation and immunosuppressive effect over the causative activated immune system and thus helps in Alopecia Areata. There are anecdotal reports of treatment with cryotherapy in AA.

# 2. Aims and Objectives

To study the clinical profiles and management outcome of Liquid Nitrogen Cryotherapy(LNC) for the treatment of unresponsive cases of AA.

# 3. Materials and Methods

We conducted a prospective study on five patients to treat the unresponsive AA with LNC who showed no response to various modalities of treatment taken for 6 months. Ethical committee clearance was taken. Thorough history and clinical evaluation with clinical pre and post photographs were recorded. The subjects were counselled in detail about the modality of treatment and written consents were taken. Topical local anesthetic cream (2.5%lidocaine and 2.5% prilocaine) was applied 1hr prior to therapy.

#### 3.1 Inclusion Criteria

- Age more than 18 years.
- Unresponsive AA not responding to other modalities of treatment taken for 6 months.

#### 3.2 Exclusion Criteria

- Associated autoimmune diseases such as thyroid disorders, vitiligo, diabetes mellitus.
- Intolerance to cold (cryoglobulinemia, cryofibrinogenemia, cold urticaria, mixed cryoglobulinemia).
- Active secondary infection like warts, herpes or bacterial infection.
- Patients not willing to follow the protocol.

We used a handheld cryo unit containing liquid nitrogen with a 1mm brass spray tip. At a distance of 2 cm from the alopecic patch, lesion was sprayed with liquid nitrogen. Dual freeze-thaw cycles of 15 seconds each, such 2 cycles were sprayed in a paint brush-like manner from one end of lesion moving up and down across each lesion. The end point was considered as development of uniform frost over the patch at the treatment site. Patients were given 3-5 sittings of LNC at 2 weeks interval. The patients were given systemic antibiotic, anti-inflammatory drugs, topical mupirocin ointment for five days post procedure to prevent secondary infection and no other treatment modality was given in between the follow up period. The clinical response was evaluated by using regrowth scale at 4<sup>th</sup> week and 8<sup>th</sup> week <sup>1</sup> (Table 1).

Final end point evaluation of patient post 3 months after the last treatment session was done to observe sustained regrowth of hair.

| Score | Regrowth | Response     |  |
|-------|----------|--------------|--|
| 0     | <10%     | No response  |  |
| 1     | 11–25%   | Poor         |  |
| 2     | 26-50%   | Fair         |  |
| 3     | 51-75%   | Satisfactory |  |
| 4     | ≥75%     | Excellent    |  |

#### Table1. Percentage of hair regrowth using regrowth scale with liquid nitrogen cryotherapy

## 4. Results

The present study was conducted on five patients of unresponsive AA cases. Out of 5 patients, there were 3 male patients and 2 female patients, aged between 19 and 32 years with a disease duration ranging from 1 to 2 years with 25%-50% of scalp involvement with only one patient involving beard area (Table2).

The positive therapeutic response was interpreted as regrowth of terminal hairs within the alopecic patches at the 4<sup>th</sup> and 8<sup>th</sup> week. Three patients (60%) showed an excellent response out of which two patients (40%) showed response at the 6<sup>th</sup> week, one patient (20%) showed response after two sitting (4<sup>th</sup> week), with no further requirement of LN cryotherapy sitting and one patient each (20%) showed satisfactory and fair response at the 8<sup>th</sup> week (Table3). Commonly seen adverse effects were slight pain, erythema, edema, erosion, crusting, dyspigmentation/ hypopigmentation, which were transient and did not require withdrawal of treatment.

| Sr.<br>No. | Age | Sex    | Anatomical<br>location | Number of patches | Duration of the disease | Previous treatment<br>taken                                   |
|------------|-----|--------|------------------------|-------------------|-------------------------|---|
| 1          | 30  | Female | Vertex                 | 2                 | 10 months               | Intralesional and<br>topical steroids, topical<br>tacrolimus. |
| 2          | 20  | Male   | Occiput                | 4                 | 13 months               | Topical steroids and tacrolimus.                              |
| 3          | 32  | Female | Vertex                 | 1                 | 9 months                | Intralesional and topical steroids,phenol.                    |
| 4          | 28  | Male   | Temporal               | 2                 | 12 months               | Systemic and topical steroids.                                |
| 5          | 19  | Male   | Beard                  | 1                 | 24 months               | Intralesional and topical steroids,anthralin.                 |

Table 2. Clinical profiles of patients

Table 3. Management outcome of patients

| Sr.no | Age/sex | Percentage of<br>regrowing hair on<br>follow-up at the<br>8 <sup>th</sup> week (%) | Response at the<br>8 <sup>th</sup> week | Sustained regrowth<br>of terminal hair at 3<br>months after the last<br>session |
|-------|---------|--|---|---|
| 1     | 30/F    | ≥75%   | Excellent                               | Present   |
| 2     | 20/M    | ≥75%   | Excellent                               | Present   |
| 3     | 32/F    | ≥75%   | Excellent                               | Present   |
| 4     | 28/M    | 51-75%   | Satisfactory                            | Present   |
| 5     | 19/M    | 26-50%   | Fair                                    | Present   |

## 5. Discussion

Alopecia Areata is a known autoimmune disease which can be seen in association with other autoimmune disorders such as vitiligo, diabetes mellitus and thyroid disorders. The massive T cell infiltrations around hair follicles, the presence of antibodies against parts of the hair follicle and hair shaft and therapeutic response to immunosuppressive agents all indicate the involvement of the immune system in the pathology of Alopecia Areata. The available therapies are directed to correcting or modulating the immune response.

Cryotherapy can act either singly or by combination of the which mechanisms resulting in regrowth of hair in AA<sup>4</sup>. After cryotherapy, initially there is vasoconstriction and then during the thaw period, there is significant vasodilation as the temperature attained is 0° Celcius<sup>5</sup>. This is hypothesized to cause regrowth of follicular hair. Also local edema and inflammation can occur post cryotherapy which is known to play a role in inducing vasodilatation<sup>6</sup>. Another speculation is that cryotherapy causes partial damage to keratinocytes of which hair follicle keratin 16 and trichohyalin are the main targets, further decreasing damage in perifollicular infiltrate. Tissue Langerhan cells are also altered which could further alter the antigen presentation process. Other theories suggest temporary paralysis of melanocytes<sup>7.8</sup>. In our study, we used longer duration of cryotherapy freeze-thaw cycle of 15 seconds each, at shorter interval that was every 2 weeks between the sessions and got excellent results. But studies done by Gita et al used 2–3 seconds freeze cycle and 3–5 seconds thaw cycle along with short duration of interval in between sessions and got comparable results<sup>2</sup>. However study conducted by Hyung *et al.*, when treated alopecic patch with cryotherapy at an interval of more than 3 weeks got poor results<sup>10</sup>.

We conducted this study on unresponsive AA patients who earlier were treated with topical, intralesional and oral steroids and now got excellent response with cryotherapy. Similar study conducted by Radmanesh *et al.* also suggested cryotherapy as an alternative method for unresponsive AA<sup>11</sup>.

Gita et al. in her study compared efficacy of LNC versus topical betamethasone lotion and concluded that both have similar efficacy and thus cryotherapy can be reserved for resistant, isolated AA cases, children or anyother individual on immunosuppresive agents apart from steroids<sup>2</sup>. However Amirnia *et al.* found poor response to cryotherapy when compared to intralesional triamcinolone, but suggested that cryotherapy still can be used as monotherapy to induce hair regrowth in special circumstances<sup>12</sup>.

Small sample size was the limitation of our study and a larger multicentric study with LNC on unresponsive



A) Pre-operative



B) 3 months post 4th sitting

Figure 1. Showing excellent response in 4 sittings with LNC.

Alopecia Areata cases would give us better insight about its effectiveness.

Unresponsive AA is common in clinical practice and treatment failures are known to occur with almost every conventional therapy whether used singly or in combination. There should be availability of alternative therapeutic approaches, which should be suitable for administration, with minimal transient side effects and should be able to produce sustainable hair regrowth. We tried LN cryotherapy as a monotherapy in patients who did not respond to other modality of treatment and excellent to good results were observed in these patients. We believe that LN cryotherapy is a cheap, easily available option and can be worth trying in the management of unresponsive AA.

# 6. Conclusion

LN cryotherapy can be worth trying modality in the treatment of unresponsive AA cases.



A) Pre-operative



B) Intra-operative

B) Intra-operative



C) 3 months post 2<sup>nd</sup> sitting







C) 3 months post 4<sup>th</sup> sitting

A) Pre-operative

Figure 3. Showing excellent response in 4 sittings with LNC.



A) Pre-operative

B) Intra-operative





B) Erosion post cryotherapy



C) 3 months post 5th

Figure 5. Showing fair response post 5th sitting.

## 7. References

A) Pre-operative

- Ganjoo S, Thappa DM. Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of Alopecia Areata. Indian J Dermatol Venereol Leprol. 2013; 79:408–17.PMid:23619446. https:// doi.org/10.4103/0378-6323.110767.
- 2. Seetharam KA. Alopecia Areata: An update. Indian J Dermatol Venereol Leprol. 2013; 79:563–75.PMid:23974575. https:// doi.org/10.4103/0378-6323.116725.
- Zawar VP, Karad GM. Liquid nitrogencryotherapy in recalcitrant Alopecia Areata: A study of 11 patients. Int J Trichol. 2016; 8:15–20. PMid:27127370

PMCid:PMC4830166.https://doi.org/10.4103/0974-7753.179403.

- Schwartz RA, Janniger CK. Alopecia Areata. Cutis. 1997; 59:238–41.
- Sharma VK, Khandpur S. Guidelines for cryotherapy. Indian J Dermatol Venereol Leprol. 2009; 75:90–100. PMid:19439873. https://doi.org/10.4103/0378-6323.51238.
- Pimentel CB, Moraes AM, Cintra ML. Angiogenic effects of cryosurgery with liquid nitrogen on the normal skin of rats, through morphometric study. An Bras Dermatol. 2014; 89:410–3. PMid:24937813 PMCid:PMC4056697. https:// doi.org/10.1590/abd1806-4841.20142249.

- Christoph T, Müller-Rover S, Audring H, Tobin DJ, Hermes B, Cotsarelis G, et al. The human hair follicle immune system: Cellular composition and immune privilege. Br J Dermatol. 2000; 142:862–73.PMid:10809841. https://doi. org/10.1046/j.1365-2133.2000.03464.x.
- Tobin DJ. Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc. 2003; 8:176–81. PMid:14582669. https://doi. org/10.1046/j.1087-0024.2003.00805.x.
- Gita F, Mohammadreza R. Liquid Nitrogen Cryotherapy vs. betamethasone lotion in the management of Alopecia Areata. J Clin Med Res. 2013; 5:18–22. https://doi. org/10.5897/JCMR11.041.

- Hong SP, Jeon SY, Oh TH, Lee WS. Retrospective study of the effect of superficial cryotherapy on Alopecia Areata. Korean J Dermatol. 2006; 44:274–80.
- 11. Radmanesh M, Azar Beig M. Cryotherapy as an alternative therapy for the treatment of recalcitrant Alopecia Areata. Iran J Dermatol. 2013; 16:49–52.
- Amirnia M, Mahmoudi SS, Karkon-Shayan F, Alikhah H, Piri R, Naghavi-Behzad M, et al. Comparative study of intralesional steroid injection and cryotherapy in Alopecia Areata. Niger Med J. 2015;56:249-52. PMid:26759508 PMCid:PMC4697211. https://doi.org/10.4103/0300-1652.165034.

How to cite this article: Zawar V, Bharati JS, Pawar M, Kumavat S and Das J. Unresponsive Alopecia Areata Treated Successfully with Liquid Nitrogen Cryotherapy: A Study of Five Patients. MVP J. Med. Sci. 2020; 7(2):288-294.